Resibufogenin
CAS No. 465-39-4
Resibufogenin ( RBG; Bufotenine; Resibufogenin )
产品货号. M18571 CAS No. 465-39-4
Resibufogenin is a cytotoxic steroid isolated from the Chinese drug ChanSu. Resibufogenin can inhibit rectifier potassium current ( I K ) and transient potassium current ( I A ), it has pathological effects on central nervous system.
纯度: 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥745 | 有现货 |
|
5MG | ¥1150 | 有现货 |
|
10MG | ¥1798 | 有现货 |
|
25MG | ¥3629 | 有现货 |
|
50MG | ¥5484 | 有现货 |
|
100MG | ¥7800 | 有现货 |
|
500MG | ¥15633 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Resibufogenin
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Resibufogenin is a cytotoxic steroid isolated from the Chinese drug ChanSu. Resibufogenin can inhibit rectifier potassium current ( I K ) and transient potassium current ( I A ), it has pathological effects on central nervous system.
-
产品描述Resibufogenin is a cytotoxic steroid isolated from the Chinese drug ChanSu. Resibufogenin can inhibit rectifier potassium current ( I K ) and transient potassium current ( I A ), it has pathological effects on central nervous system. Resibufogenin corrects hypertension in a rat model of human preeclampsia, it not only prevents the advent of hypertension and proteinuria, but also the development of intrauterine growth restriction. Resibufogenina's major metabolic pathway in the human liver is CYP3A4 dominantly mediated 5β-hydroxylation .
-
同义词RBG; Bufotenine; Resibufogenin
-
通路Angiogenesis
-
靶点PDE
-
受体Others
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number465-39-4
-
分子量384.51
-
分子式C24H32O4
-
纯度98%
-
溶解度DMSO : 100 mg/mL 260.07 mM;
-
SMILESCC12CCC(CC1CCC3C2CCC4(C35C(O5)CC4C6=COC(=O)C=C6)C)O
-
化学全称14,15beta-Epoxy-3beta-hydroxy-5beta-bufa-20,22-dienolide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
产品手册
关联产品
-
5,7-Diacetoxy-8-meth...
5,7-Diacetoxy-8-methoxyflavone is derived from the roots of Scutellaria baicalensis and inhibits cAMP phosphodiesterase.
-
BRL 50481
BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15 12.1 62 and 490 μM for PDE7A PDE7B PDE4 and PDE3 respectively.
-
ITI214
ITI-214 is a potent, selective, orally active phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM.